Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Wyeth wrestles with Prempro suits
Two women in Nevada claimed that Prempro and Premarin led to them developing breast cancer, and rather than go to trial, Wyeth paid the women an undisclosed settlement amount. The women asserted that Wyeth did not adequately warn them about their increased risk of developing breast cancer because of taking the menopause medications.
According to Wyeth, the company has more than 5,000 lawsuits regarding the menopause meds facing it, but plaintiff attorneys say the real number is likely double that. It has lost four out of seven cases so far. Prizer will also continue to hit the courts over its drug, Provera. So far, it's zero for two.
On July 11, New Jersey Judge Jamie Happas dismissed two lawsuits aimed at Wyeth and Pfizer's Pharmacia & Upjohn unit, saying the plaintiffs did not provide sufficient proof that the companies failed to warn them adequately.
The drugs are still on the market, despite the fact that women taking these medicines have almost a 25 percent increased risk of breast cancer, according to a 2002 study. Over 6 million women have taken the drugs, which have brought Wyeth in excess of $2 billion dollars in sales.
- see the LA Times story
- read more at MarketWatch
Related Articles:
Wyeth appealing two hormone verdicts
Court dismisses lawsuit on Wyeth's Prempro
Jury fines Wyeth $134.5M in hormone suit
Wyeth asks judge to cut $134M award
Comments
Sometimes I wonder what is wrong with these Judges. My mother died of ovarian cancer from
taking Premarin. She also had gallbadder poblems and heart problems which lead to a triple bi-pass and a pacemaker. If these Judges had a loved one in thier family suffer from cancer, I believe thier decesion would be much different. They did not properly warn of the dangers. Why is this drug still prescribed? I wish they would settle instead of dragging all of this out.
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


